CGL
PRME icon

Clarius Group LLC’s Prime Medicine PRME Stock Holding History

Clarius Group LLC’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$55.8K Hold
16,080
– – ﹤0.01% 382
2025
Q3 		$89.1K Hold
16,080
– – 0.01% 395
2025
Q2 		$39.7K Hold
16,080
– – ﹤0.01% 478
2025
Q1 		$32K Hold
16,080
– – ﹤0.01% 480
2024
Q4 		$47K Hold
16,080
– – ﹤0.01% 448
2024
Q3 		$62.2K Hold
16,080
– – ﹤0.01% 449
2024
Q2 		$82.7K Hold
16,080
– – 0.01% 439
2024
Q1 		$113K Hold
16,080
– – 0.01% 471
2023
Q4 		$142K Hold
16,080
– – 0.01% 464
2023
Q3 		$153K Hold
16,080
– – 0.01% 443
2023
Q2 		$236K Hold
16,080
– – 0.02% 453
2023
Q1 		$198K Hold
16,080
– – 0.02% 483
2022
Q4 		$299K Buy
+16,080
New +$290K 0.03% 385

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Clarius Group LLC's PRME Position: Q4 2025 in Review

Clarius Group LLC held its Prime Medicine (PRME) position steady in Q4 2025 at 16,080 shares worth $55.8K. The position accounts for ﹤0.01% of the portfolio, ranked #382.

Clarius Group LLC first reported a position in PRME in Q4 2022 and has held it in 13 quarters since. The position peaked at $299K in Q4 2022. 183 funds tracked by Wall St. Rank hold PRME as of Q4 2025.

  • Clarius Group LLC held 16,080 shares of Prime Medicine worth $55.8K as of Q4 2025.
  • Clarius Group LLC left its Prime Medicine share count unchanged in Q4 2025.
  • Prime Medicine made up ﹤0.01% of Clarius Group LLC's portfolio in Q4 2025, its #382 holding.
  • Clarius Group LLC first reported a position in Prime Medicine in Q4 2022 and has held it in 13 quarters since.
  • Clarius Group LLC's Prime Medicine position peaked at $299K in Q4 2022.
  • 183 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2025.

Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.